Skip to the page

Data / Drug companies / Novo Nordisk

Novo Nordisk: 92 products in the FDA NDC directory, labeler code 0169

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Novo Nordisk (labeler code 0169) lists 92 products in the FDA National Drug Code Directory, covering 22 finished drugs by generic name. By type: 64 prescription drugs, 22 plasma derivatives. Its main marketing category is biologics (BLA). The newest product started marketing on August 11, 2026.

The request: Watch Novo Nordisk (FDA labeler code 0169): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0169
Products in commercial distribution
92
Packages
135
Finished drugs by generic name
22
Prescription products
64
Over the counter products
6
Flagged as original packager
46 of 46 products that carry the flag
Started marketing in the last 12 months
9
Products with a marketing end date set
3
Earliest marketing start
June 25, 1991
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Biologics (BLA)6368.5%
New drug applications (NDA)2931.5%

Products by type

TypeProductsShare
Prescription drugs6469.6%
Plasma derivatives2223.9%
Over the counter drugs66.5%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Semaglutide142
Insulin aspart114
Coagulation factor viia (recombinant)81
Antihemophilic factor (recombinant), glycopegylated-exei71
Human insulin62
Oral semaglutide61
Antihemophilic factor recombinant62
Somatropin46
Coagulation factor ix recombinant, glycopegylated41
Nedosiran31
Concizumab31
Somapacitan-beco31
Insulin aspart injection31
Insulin degludec33
Liraglutide211
Dasiglucagon21
Insulin icodec-abae21
Estradiol153
Water injection13
Coagulation factor xiii a-subunit (recombinant)11
Macimorelin acetate12
Insulin degludec and liraglutide11

Dosage forms

Dosage formProductsShare
Injection, solution4548.9%
Kit2628.3%
Tablet1010.9%
Injection, suspension88.7%
Insert11.1%
Injection11.1%
Granule, for solution11.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

ClassProducts
GLP-1 Receptor Agonist23
Insulin Analog18
Insulin6
Recombinant Human Growth Hormone4
Tissue Factor Pathway Inhibitor Antagonist3
Antihypoglycemic Agent2
Estrogen1
Growth Hormone Secretagogue Receptor Agonist1

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Awiqli0169-3170Injection, solutionBiologics (BLA)August 11, 2026
Awiqli0169-3105Injection, solutionBiologics (BLA)August 3, 2026
Ozempic0169-1715TabletNew drug applications (NDA)April 27, 2026
Ozempic0169-1709TabletNew drug applications (NDA)April 27, 2026
Ozempic0169-1704TabletNew drug applications (NDA)April 27, 2026
Wegovy0169-4425TabletNew drug applications (NDA)January 6, 2026
Wegovy0169-4415TabletNew drug applications (NDA)January 6, 2026
Wegovy0169-4409TabletNew drug applications (NDA)January 6, 2026
Wegovy0169-4404TabletNew drug applications (NDA)January 6, 2026
Alhemo0169-2084Injection, solutionBiologics (BLA)February 19, 2025
Alhemo0169-2081Injection, solutionBiologics (BLA)February 19, 2025
Alhemo0169-2080Injection, solutionBiologics (BLA)February 19, 2025
Rivfloza0169-5308Injection, solutionNew drug applications (NDA)February 19, 2024
Rivfloza0169-5307Injection, solutionNew drug applications (NDA)February 19, 2024
Rivfloza0169-5306Injection, solutionNew drug applications (NDA)February 19, 2024
Zegalogue0169-1913Injection, solutionNew drug applications (NDA)June 26, 2023
Zegalogue0169-1912Injection, solutionNew drug applications (NDA)June 26, 2023
Sogroya0169-2037Injection, solutionBiologics (BLA)May 1, 2023
Sogroya0169-2035Injection, solutionBiologics (BLA)May 1, 2023
Sogroya0169-2030Injection, solutionBiologics (BLA)May 1, 2023
Ozempic0169-4181Injection, solutionNew drug applications (NDA)October 7, 2022
Rebinyn0169-7903KitBiologics (BLA)August 11, 2022
Ozempic0169-4772Injection, solutionNew drug applications (NDA)April 25, 2022
Macrilen0169-1401Granule, for solutionNew drug applications (NDA)January 31, 2022
Wegovy0169-4915Injection, solutionNew drug applications (NDA)June 5, 2021

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.